-
AbbVie Inc. (ABBV $218.34)
- $218.34 P/E (TTM): 104.47X Cap: $385.71B
- View ABBV Profile
- View Questions on ABBV
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
AbbVie Inc. (ABBV $218.34)
- $218.34 P/E (TTM): 104.47X Cap: $385.71B
- View ABBV Profile
- View Questions on ABBV
-
Cybin Inc Com (CX $0.14)
-
COMPASS Pathways Plc (CMPS $5.20)
- $5.20 Cap: $498M
- View CMPS Profile
- View Questions on CMPS
-
Mind Medicine (MindMed) Inc. (MNMD $9.44)
- $9.44 Cap: $709M
- View MNMD Profile
- View Questions on MNMD
Q: What is your opinion of ABBV buying an experimental drug derived in the psychedelic space from private company Gilgamesh for 1.2B?. Do you think with some of these psychedelic companies now getting phase 2 and phase 3 trials wrapped up on their potential drug offerings that the psychedelic market might get some legs in the near future as the big pharma companies look for the next big thing. ? With these being very spec who would be you picks in the space for fun money?
-
AbbVie Inc. (ABBV $218.34)
- $218.34 P/E (TTM): 104.47X Cap: $385.71B
- View ABBV Profile
- View Questions on ABBV
Q: Hi there,
ABBV has been on a decent run since July. I assume their mostly positive quarterly report indicating lots of activity in their drug pipeline is one reason plus healthcare seems to be showing a bit of life.
How do you see it’s valuation is it an ADD/BUY in a diversified portfolio for growth and income?
ABBV has been on a decent run since July. I assume their mostly positive quarterly report indicating lots of activity in their drug pipeline is one reason plus healthcare seems to be showing a bit of life.
How do you see it’s valuation is it an ADD/BUY in a diversified portfolio for growth and income?
-
Amgen Inc. (AMGN $276.39)
- $276.39 P/E (TTM): 22.58X Cap: $148.79B
- View AMGN Profile
- View Questions on AMGN
-
Gilead Sciences Inc. (GILD $114.55)
- $114.55 P/E (TTM): 22.77X Cap: $142.13B
- View GILD Profile
- View Questions on GILD
-
AbbVie Inc. (ABBV $218.34)
- $218.34 P/E (TTM): 104.47X Cap: $385.71B
- View ABBV Profile
- View Questions on ABBV
-
Abbott Laboratories (ABT $133.73)
- $133.73 P/E (TTM): 16.78X Cap: $232.75B
- View ABT Profile
- View Questions on ABT
-
The Cigna Group (CI $302.76)
- $302.76 P/E (TTM): 16.64X Cap: $80.81B
- View CI Profile
- View Questions on CI
-
Johnson & Johnson (JNJ $178.06)
- $178.06 P/E (TTM): 19.04X Cap: $428.82B
- View JNJ Profile
- View Questions on JNJ
-
Medtronic plc. (MDT $94.03)
- $94.03 P/E (TTM): 26.05X Cap: $120.61B
- View MDT Profile
- View Questions on MDT
-
Savaria Corporation (SIS $20.51)
- $20.51 P/E (TTM): 26.64X Cap: $1.46B
- View SIS Profile
- View Questions on SIS
- View Reports on SIS
Q: I am mostly content with my health care stocks with the exception of MDT. It has been essentially flat since about 2016 except for the dividend. It did peak around 2022 but has fallen down to previous levels.
What do you think of the longer term for MDT?
Would you make any other changes for slow but reliable growth and higher end of dividends.
As always, thank you for the great service.
What do you think of the longer term for MDT?
Would you make any other changes for slow but reliable growth and higher end of dividends.
As always, thank you for the great service.
Insiders
Share Information
SEC Filings
News and Media